RAD101 is the Company’s novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, ...

Human brain organoid studies demonstrated significant improvement in neuronal growth, morphology, and function; These findings highlight the potential of the porosome – a centra ...

The documented technical foundation supports a Q1 2026 commercial launch featuring Digital Landia's B2C AgenticPet app and PetVivo's B2B veterinary platform with white-labeled AI diagnostic assistance ...

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive ...

The summit includes presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of obesity and related disorders.

NextCure intends to use the net proceeds from the offering for general working capital needs, extending the company’s cash runway into the first half of 2027, which is beyond the planned first half of ...

LifeMD’s shift from compounded GLP-1s to direct partnerships with leading pharmaceutical manufacturers is central to its long-term growth strategy, reinforcing its commitment to emerging regulatory ...

The Donor Selection & Cell Source Summit, hosted by Hanson Wade, brings together leaders from industry and academia to address critical bottlenecks in donor screening, cell sourcing, and process ...

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Paris, 17 novembre 2025. À l'occasion du premier sommet Choose France dédié aux entreprises françaises, Sanofi confirme la place essentielle de la France dans sa stratégie industrielle, scientifique e ...

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...

These subgroup insights will guide trial design, patient selection, and endpoint strategy for Autonomix’s upcoming U.S.-based multicenter clinical study, currently planned to begin in 2026, which will ...